Ying Q L, Kemme M, Saunders D, Simon S R
Department of Pathology, State University of New York at Stony Brook, 11794, USA.
Am J Physiol. 1997 Mar;272(3 Pt 1):L533-41. doi: 10.1152/ajplung.1997.272.3.L533.
Secretory leukoprotease inhibitor (SLPI) is one of the major physiological inhibitors protecting respiratory epithelium from attack by excess human leukocyte elastase (HLE), a serine protease released by neutrophils upon activation in response to inflammatory stimuli. Reaction with N-chlorotaurine, a major long-lived oxidant generated by activated neutrophils, oxidized all four methionine residues, but no other amino acids, in SLPI, resulting in substantial diminution of its elastase inhibitory activity. Oxidation of the P1' residue, Met73, accounted for most of the diminution in activity since a site-directed mutant of SLPI with leucine at the P1' position retained much higher residual activity after reaction with N-chlorotaurine. The diminished activity of oxidized SLPI could be almost completely restored when an iduronate-containing glycosaminoglycan, such as heparin, heparan sulfate, or dermatan sulfate, was added to the reaction medium. Addition of a sulfated glucuronate-containing glycosaminoglycan, chondroitin 4- or 6-sulfate, to the medium resulted in smaller but significant restoration of the lost activity, whereas the effects of hyaluronic acid and keratan sulfate were negligible. Kinetic analysis revealed that glycosaminoglycans greatly accelerated the association of oxidized SLPI and HLE, whereas iduronate-containing glycosaminoglycans also stabilized the enzyme-inhibitor complex formed. Based on these findings, we suggest that oxidized SLPI is a functionally active form of the inhibitor but that expression of its elastase inhibitory activity is regulated by sulfated uronate-containing glycosaminoglycans. Because its methionine residues have already been oxidized, this form of SLPI is resistant to the oxidant species that selectively attacks methionine residues in proteins. These findings indicate that SLPI may play a previously unexpected role in elastase inhibitory function in the lungs when significant inflammation is present.
分泌型白细胞蛋白酶抑制剂(SLPI)是保护呼吸道上皮免受过量人白细胞弹性蛋白酶(HLE,一种中性粒细胞在炎症刺激激活后释放的丝氨酸蛋白酶)攻击的主要生理抑制剂之一。与N - 氯牛磺酸(一种由活化中性粒细胞产生的主要长效氧化剂)反应,氧化了SLPI中所有四个甲硫氨酸残基,但没有氧化其他氨基酸,导致其弹性蛋白酶抑制活性大幅降低。P1'残基Met73的氧化是活性降低的主要原因,因为在P1'位置具有亮氨酸的SLPI定点突变体在与N - 氯牛磺酸反应后保留了更高的残余活性。当向反应介质中添加含艾杜糖醛酸的糖胺聚糖,如肝素、硫酸乙酰肝素或硫酸皮肤素时,氧化型SLPI降低的活性几乎可以完全恢复。向介质中添加含硫酸葡萄糖醛酸的糖胺聚糖,硫酸软骨素4 - 或6 - 硫酸盐,导致失去的活性有较小但显著的恢复,而透明质酸和硫酸角质素的作用可忽略不计。动力学分析表明,糖胺聚糖极大地加速了氧化型SLPI与HLE的结合,而含艾杜糖醛酸的糖胺聚糖也稳定了形成的酶 - 抑制剂复合物。基于这些发现,我们认为氧化型SLPI是抑制剂的一种功能活性形式,但其弹性蛋白酶抑制活性的表达受含硫酸化糖醛酸的糖胺聚糖调节。由于其甲硫氨酸残基已经被氧化,这种形式的SLPI对选择性攻击蛋白质中甲硫氨酸残基的氧化物种具有抗性。这些发现表明,当存在显著炎症时,SLPI可能在肺部弹性蛋白酶抑制功能中发挥先前未预料到的作用。